-
2024-514409-78-01
9
2019-07-26
relapsed / refractory or progressive high risk malignant disease
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)
-
2023-508988-73-00
5
2025-10-29
Cytomegalovirus (CMV) infection in children and adolescents who have r
-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema
-
2025-521096-31-00
5
2025-10-02
Chronic Hepatitis C Virus (HCV) Infection
-
2024-520031-33-00
4
2025-09-16
Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2024-518457-42-00
4
2025-08-28
chronic kidney disease
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-520062-54-00
4
2025-07-23
Chronic Hepatitis D Virus (HDV) Infection
-
2024-517143-31-00
4
2025-07-18
Autosomal Dominant Polycystic Kidney Disease
-
2024-515919-22-00
5
2025-06-02
Chronic Hepatitis D Virus (HDV) Infection
-
2024-511754-41-00
4
2025-05-29
idiopathic pulmonary fibrosis
-
2024-518207-22-00
4
2025-05-15
Hereditary Angioedema
-
2024-516609-22-00
5
2025-04-15
Primary Sjögren’s Disease
-
2023-506880-32-01
1
2025-04-14
Pulmonary Disease, Chronic Obstructive
-
2024-514942-35-00
3
2025-04-11
Type 1 interferonopathies
-
2024-515741-42-00
5
2025-03-28
hereditary angioedema due to C1 esterase inhibitor deficiency (Type 1
-
2024-514292-18-00
5
2025-03-24
Primary Sclerosing Cholangitis (PSC)